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ABSTRACT 
The present work was aimed at formulation development, evaluation and comparative study of the effects of ethyl cellulose in Itopride HCL CR 
pellets. The controlled release polymers used for the present study were Ethylcellulose N-14 and Ethylcellulose N-20. The formulated pellets were 
evaluated for various pellet properties, like hardness, bulk density, tapped density, cars index and dissolution rate. Comparative evaluation of the 
above-mentioned parameters established the superiority of the pellets formulated with Ethylcellulose those formulated with different grades. 
Keywords: "PPI"s, Laryngopharyngeal, 
INTRODUCTION 
A peptic ulcer is a hole in the Gut lining of the stomach, duodenum, 
or esophagus. A peptic ulcer of the stomach is called a gastric ulcer 
of the duodenum, a duodenal ulcer, and of the esophagus, an 
esophageal ulcer. An ulcer occurs when the lining of these organs is 
corroded by the acidic digestive juices which are secreted by the 
stomach cells. 
Peptic ulcer disease is common, affecting millions of Americans 
yearly Proton pump inhibitors (or "PPI"s) are a group of drugs 
whose main action is a pronounced and long-lasting reduction of 
gastric acid production. 
These drugs are utilized in the treatment of many conditions such as 
Dyspepsia, Peptic ulcer disease (PUD), Gastroesophageal reflux 
disease Laryngopharyngeal Reflux Disease, Barrett's esophagus, 
prevention of stress gastritis. Gastrinomas and other conditions that 
cause hypersecretion of acid, Zollinger-Ellison syndrome. 
Proton pump inhibitors act by irreversibly blocking the 
hydrogen/potassium adenosine triphosphatase enzyme system (the 
H+/K+ ATPas) or more commonly just gastric proton pump) of the 
gastric parietal cell. The proton pump is the terminal stage in gastric 
acid secretion, being directly responsible for secreting H+ ions into 
the gastric lumen, making it an ideal target for inhibiting acid 
secretion. 
MATERIALS AND METHODS 
 Materials 
Itopride HCL (purity 99%) was procured from Cipla pharmaceutical, 
Mumbai and PVPK_30 from VAV Life Science Pvt. Ltd. Mumbai, India. 
Hydroxy Propyl Methyl Cellulose (grade 1) (AR), Buffer Solution pH-
7 (LR), Chloroform (LR), Di-methyl Sulphoxide (LR), Buffer Solution 
pH-4 (LR), Dichloromethane (AR) was purchased from Central Drug 
House (P) Ltd. New Delhi, India. Hydroxy Propyl Methyl Cellulose 
(grade 2) (LR) and Talc was purchased from E. Merck Ltd., Mumbai, 





Determination of bulk density and tap density 
An accurately weighted quantity of the powder (W) was carefully 
poured into the granulated cylinder and volume (Vo) was measured. 
Then the graduated cylinder was closed with lid .set into the density  
 
determination apparatus (bulk density apparatus)the density 
apparatus was set for  500 taps,750 taps , and 1250 taps. 
After that the volume (Vf) was measured and continued the 
operation till the two consecutive reading were equal. The bulk 
density and the tapped density were calculated using the formulas. 
Bulk Density – W/Vo 
Tapped Density- W/Vf 
Where W- Weight of the powder 
Vo - Initial volume (s) 
Vf - Final volume. 
Bulk density of ItoprideHCl powder was found to be 0.39g/ml. 
Tap density of ItoprideHCl powder was found to be 0.62g/ml. 
Hausner ratio 
It indicates the flow properties of the powder and measured by the 
ratio of Tapped density to bulk density. 
Hauser ratio- Tapped density /Bulk density 
Table No 1: Range of hausner ratio and its properties 
No.  Hausner ratio    Properties 
1   0-1.2     Free flowing 
2   1.2-1.6     Cohesive powder 
 





The main aim of sieve analysis was to determine the different size of 
drug Particles present. series of standard  sieve were stacked one 
above the other so that sieves with larger pore size (less sieve 
number)occupy top position  followed by sieve of decreasing pore 




A series of sieves were arranged in the order of their deceasing pore 
diameter (increasing sieve number) i.e. sieve no. ASTM 40, 60, 80, 
100 with 40grams of drug were weighed accurately and transferred 
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to sieve 40 which were kept on top. The sieves were shaken for 
about 5-10 minutes. 
Then the drug retained on each sieves were taken, Weighted 
separately and expressed in terms of percentage 69.4% itoprideHCl 
powder pass through sieve 100 (NLT 65% should pass through 100 
mesh). 
 
Solubility- freely soluble in water, methanol. 
Melting Point-192oC 
Description- white power. 
METHODS OF PREPARING PELLETS 
Compaction and drug layering are the most widely used pelletization 
techniques in harmaceutical industry. Of the compaction techniques, 
extrusion and spheronization is the most popular method. Recently, 
however, melt pelletization has been used frequently in making 
compaction pellets using a different type of equipment, e.g. a high-
shear mixer. Other pelletization methods such as Solution   Layering 
SOLUTION   LAYERING 
Solution and suspension layering involves the deposition of 
successive layers of solution or suspensions of drug substances and 
binder over the starter and non-peril seeds, which is an inert 
material or crystals and granules of the same drug. In fact the 
coating process involved in general is applicable to solution or 
suspension layering technology. 
Consequently conventional coating pans, fluidized beds, centrifugal 
granulators, wurster coaters have been used successively to 
manufacture pellets by this method. The  
Formulation and development of pellets 
In this method mainly 3 steps 
                                                A.  Drug Loading 
                                                          B. Seal Coating 
                                                          C.  S.R Coating 
Drug Loading 
Solution1: Required quantity of drug (Itopride hcl)was dissolved in 
isopropyl alcohol (IPA).to this solution add tri ethyl citrate , 
pvpk_30,talc, titanium dioxide, mix properly then filtrate the 
solution . 
Drying 
Dry the solution at 45c for 2hours. 
Soiution2 (Seal coating):  




In S.R Coating ethyl cellulose dissolved in isopropyl alcohol and 




Shifting or sieving 
Filling capsule according to weight 
Table 2: Formulation of Itopride HCl pellets 
Ingredients IPF 





CONVENTIONAL PAN SYSTEM 
The standard coating pan system consists of a circular metal pan 
mounted somewhat angularly on a stand, the pan is rotated on its 
horizontal axis by a motor, the hot air is directed into the pan and 
onto the bed surface, and is exhausted by means of ducts positioned 
through the front of the pan .Coating solutions are applied by 
spraying the material on the bed surface. 
EVALUATION OF ENTERIC COATED PELLETS: 
 DISSOLUTION STUDIES OF ITOPRIDE PELLETS 
Parameter for Dissolution Study 
Apparatus Tablet dissolution tester USP 
Method USP Type II Apparatus (Paddle Method) 
Dissolution medium 0.1 N Hydrochloric acid (900 ml) 
Temperature -37 + 0.5° C 
Speed-50 rpm 
in-vitro release studies were carried out in the dissolution test 
apparatus (USP Type II). The tests were carried out in 900 ml of 
0.1N HCl for 12 hrs at 50 rpm at 37±0.5oC. 10 ml of the aliquot were 
withdrawn at different predetermined time intervals (0.5, 1, 2, 4, 6, 
8, 10, 12 hr) and filtered. 
The required dilutions were made with 0.1N HCl and the solution 
was analyzed for the drug content by UV spectrophotometer 
detecting at λ max 247 nm, 0.1N HCl was replaced in the vessel after 
each withdrawal to maintain sink condition. From this percentage 
drug release was calculated and this was plotted against function of 
time to study the pattern of drug release. 
PROCEDURE 
One tablet was placed to each of the six dissolution vessel containing 
900 ml of dissolution medium. The apparatus was run for 24 hours. 
After each specified interval, 10 ml of sample was withdrawn and 
the solution was filtered through membrane filters. 
Table 3: Release studies of Coating of Itopride HCl pellets with 
Ethyl cellulose N-20 
Time(Hrs) IPF1 IPF2 IPF3 IPF4 IPF5 Marketed 
1 61 46 26 12 10 19 
3 76 58 44 36 26 35 
6 95 72 63 45 34 65 
9 95 88 81 59 51 76 
12 95 96 94 76 66 87 
Table 4: Release studies of Coating of Itopride HCl pellets with 
Ethyl cellulose N-50 
Time(Hrs) IPF6 IPF7 IPF8 IPF9 IPF10 Marketed 
1 55 35 18 11 8 19 
3 72 56 38 25 19 35 
6 88 69 67 42 32 65 
9 92 82 83 57 49 76 
12 94 95 97 71 62 87 
 
RESULTS AND DISCUSSION 
 
STANDARD CURVE FOR ITOPRIDE HCL 
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Fig 1:  Standard Curve of Etopride HCL 
 
in-vitro DISSOLUTION TEST 
 




Fig 2:  Comparative study of percentage drug release with 
Innovator product 
 
Fig 3:  Comparative study of percentage drug release with 
Innovator product from Top-spray, Tangential-spray Bottom-
spray equipment 
DESCRIPTION–   Fine Spherical shape having sr coated pellets. 
DIMENSIONS– Size of the pellets in the range of 1.28 -1.40 mm 
determine by using vernier caliper. 
HARDNESS– Hardness of pellets in the range of 9 -17 N determined 
by Dr.Schieuniger hardness tester. 
Table No.6 Hardness of pellets of different formulation 
Formulation F1 F2 F3 F4 F5 
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ITOPRIDE HCL with IPA 
 
 
ITOPRIDE HCl with HPMC E15 
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 There is no interaction in between Drug and excipients. 
 In the Dissolution report Ethylcellulose N-50 (4%) IPF8 
shows better release studies. 
CONCLUSION 
The present work on as controlled drug delivery system for 
ItoprideHCl from the present study, it can be concluded that 
Ethylcellulose N-50 grade was shows better Drug release studies 
using 4% Solution for controlled release of ItoprideHCl and there is 
no interaction observed in Infrared Spectroscopy. 
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